Evidence map›Paper›PMID 35746441›Full record

ArticleVaccines2022

Select Whole-Cell Biofilm-Based Immunogens Protect against a Virulent Staphylococcus Isolate in a Stringent Implant Model of Infection.

Stephen J Dollery, Janette M Harro, Taralyn J Wiggins, Brendan P Wille, Peter C Kim, John K Tobin, Ruth V Bushnell, Naomi J P E R Tasker, David A MacLeod, Gregory J Tobin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Stephen J DolleryBiological Mimetics, Inc., Frederick, MD 21702, USA.ORCID 0000-0002-1712-3811
Janette M HarroDepartment of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore, MD 21201, USA.
Taralyn J WigginsBiological Mimetics, Inc., Frederick, MD 21702, USA.
Brendan P WilleDepartment of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore, MD 21201, USA.
Peter C KimDepartment of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore, MD 21201, USA.ORCID 0000-0002-5398-773X
John K TobinBiological Mimetics, Inc., Frederick, MD 21702, USA.
Ruth V BushnellBiological Mimetics, Inc., Frederick, MD 21702, USA.
Naomi J P E R TaskerBiological Mimetics, Inc., Frederick, MD 21702, USA.
David A MacLeodBiological Mimetics, Inc., Frederick, MD 21702, USA.
Gregory J TobinBiological Mimetics, Inc., Frederick, MD 21702, USA.ORCID 0000-0002-8396-0466
Biological Mimetics (United States) · USUniversity of Maryland, Baltimore · US

Funding

Development of a Staph Aureus VaccineR43AI174497 · NIAID · BIOLOGICAL MIMETICS, INC. · PI DOLLERY, STEPHEN JEFFREY · 2023 to 2024
$593k
A Subunit Vaccine Against Acinetobacter BaumanniiR43AI189041 · NIAID · BIOLOGICAL MIMETICS, INC. · PI Stephen Jeffrey Dollery · 2025 to 2026
$566k
Whole-Cell Vaccine Development for MRSAR43AI145457 · NIAID · BIOLOGICAL MIMETICS, INC. · PI DOLLERY, STEPHEN JEFFREY · 2019 to 2019
$225k
NIAID NIH HHS R43 AI145457NIAID NIH HHS R43 AI174497NIAID NIH HHS R43 AI189041NIH HHS R43AI145457
6 · The paper itself

Abstract

Many microbes of concern to human health remain without vaccines. We have developed a whole-microbe inactivation technology that enables us to rapidly inactivate large quantities of a pathogen while retaining epitopes that were destroyed by previous inactivation methods. The method that we call UVC-MDP inactivation can be used to make whole-cell vaccines with increased potency. We and others are exploring the possibility of using improved irradiation-inactivation technologies to develop whole-cell vaccines for numerous antibiotic-resistant microbes. Here, we apply UVC-MDP to produce candidate MRSA vaccines which we test in a stringent tibia implant model of infection challenged with a virulent MSRA strain. We report high levels of clearance in the model and observe a pattern of protection that correlates with the immunogen protein profile used for vaccination.

Indexed as

biofilmclearanceMRSAprosthetic implantprotectionstaphylococcusvaccine

Identifiers

PMID35746441
PMCPMC9231243
OpenAlexW4281487511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.